Inavolisib (GDC-0077) is a potent, orally available, and selective PI3Ka inhibitor (IC50=0.038 nM).
| Product Name | Inavolisib |
| Synonyms | GDC-0077 |
| CAS Number | 2060571-02-8 |
| Related CAS | |
| Molecular Formula | C18H19F2N5O4 |
| Molecular Weight | 407.378 |
| SMILES | C[C@H](NC1=CC=C2C3=NC(=CN3CCOC2=C1)N1[C@@H](COC1=O)C(F)F)C(N)=O |
| Purity (HPLC) | >= 95% |
| Physical Appearance | White solid |
| Solubility | DMSO, DMF |
| Shipping Conditions | Room Temperature |
| Storage Conditions | Refrigerated |
| Shelf Life | 12 months after the date of delivery |
| Regulatory Statement | For Research Use Only |
References
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT04191499 (accessed Mar 29, 2022).
Documents
Datasheet COA MSDS
Citations
If you know of a paper that uses this product from Tenova Pharma, please let us know.